CLINICAL_TRIALS trial_result · 2021-04-12

Clinical Trial Update: A Pharmacokinetic Study of MP-214 in Patients With Schizophrenia [Phase 2, Phase 3]

This is a completed pharmacokinetic study of MP-214 in patients with schizophrenia. Results were posted on April 12, 2021.

Upgrade for the full analysis, importance score, and drug timeline.

Sponsor: Tanabe Pharma Corporation | Conditions: Schizophrenia | Phase 2, Phase 3 | Status: COMPLETED | Results posted: 2021-04-12